Clinical Trial Update: Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing three doses of lasmiditan (50 mg, 100 mg, 200 mg) to placebo for acute treatment of migraine has been completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Without Aura
• Migraine with Aura

Drugs mentioned

• Lasmiditan (Lasmiditan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine With or Without Aura | Phase 3 | Status: COMPLETED | Results posted: 2018-07-30